Gary Roubin Buys 90,000 Shares of InspireMD (NYSE:NSPR) Stock

Key Points

• Insider buying: InspireMD director Gary Roubin bought 90,000 shares at $1.18 each, a transaction worth $106,200. After the purchase, he owned 834,478 shares, increasing his stake by 12.09%.
• Stock performance: NSPR shares traded down to $1.15, near the company’s 12-month low of $1.02 and well below its 12-month high of $2.93. The stock’s market cap is about $53.93 million.
• Analyst sentiment: Wall Street remains broadly bullish, with three analysts rating the stock a Buy and an average price target of $4.50. Recent targets ranged from $3.00 to $6.00.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Gary Roubin purchased 90,000 shares of the firm's stock in a transaction on Thursday, May 7th. The shares were acquired at an average cost of $1.18 per share, with a total value of $106,200.00. Following the completion of the acquisition, the director directly owned 834,478 shares in the company, valued at $984,684.04. The trade was a 12.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

InspireMD Price Performance

Shares of NSPR traded down $0.01 during mid-day trading on Friday, reaching $1.15. The company's stock had a trading volume of 188,622 shares, compared to its average volume of 174,055. InspireMD, Inc. has a 12-month low of $1.02 and a 12-month high of $2.93. The stock has a market cap of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. The company's 50 day moving average is $1.51 and its 200 day moving average is $1.75.

Hedge Funds Weigh In On InspireMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in InspireMD during the 4th quarter valued at approximately $30,000. Virtu Financial LLC purchased a new position in shares of InspireMD in the 4th quarter valued at approximately $31,000. Creative Planning acquired a new position in shares of InspireMD in the second quarter valued at approximately $44,000. Uniting Wealth Partners LLC acquired a new position in shares of InspireMD in the third quarter valued at approximately $51,000. Finally, Legato Capital Management LLC purchased a new stake in shares of InspireMD during the fourth quarter worth approximately $48,000. Hedge funds and other institutional investors own 44.78% of the company's stock.

Wall Street Analyst Weigh In

NSPR has been the subject of a number of research analyst reports. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday. Loop Capital set a $5.00 price objective on InspireMD in a research note on Tuesday, February 24th. Maxim Group assumed coverage on InspireMD in a report on Monday, February 2nd. They issued a "buy" rating and a $6.00 price objective for the company. Finally, Piper Sandler restated an "overweight" rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.